Is Genmab AS Stock a Good Investment?
Genmab AS Investment Advice | GMAB |
- Examine Genmab AS's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Genmab AS's leadership team and their track record. Good management can help Genmab AS navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Genmab AS's business and its evolving consumer preferences.
- Compare Genmab AS's performance and market position to its competitors. Analyze how Genmab AS is positioned in terms of product offerings, innovation, and market share.
- Check if Genmab AS pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Genmab AS's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Genmab AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Genmab AS is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Modest | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Almost mirrors the market | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Strong | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Genmab AS Stock
Researching Genmab AS's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). The book value of the company was currently reported as 483.85. The company has Price/Earnings To Growth (PEG) ratio of 1.27. Genmab AS had not issued any dividends in recent years. The entity had 5:1 split on the 1st of May 2018.
To determine if Genmab AS is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Genmab AS's research are outlined below:
| Genmab AS is unlikely to experience financial distress in the next 2 years | |
| Genmab AS has a strong financial position based on the latest SEC filings | |
| Latest headline from investorplace.com: GMAB Stock Earnings Genmab Beats EPS, Beats Revenue for Q1 2024 |
Genmab AS Quarterly Liabilities And Stockholders Equity |
|
Genmab AS uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Genmab AS. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Genmab AS's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 14th of February 2024 Upcoming Quarterly Report | View | |
| 8th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Genmab AS's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Genmab AS's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2021-08-11 | 2021-06-30 | 0.0723 | 0.08 | 0.0077 | 10 | ||
2021-05-21 | 2021-03-31 | 0.23 | 0.27 | 0.04 | 17 | ||
2019-08-20 | 2019-06-30 | 0.27 | 0.2 | -0.07 | 25 | ||
2021-11-10 | 2021-09-30 | 0.1315 | 0.21 | 0.0785 | 59 | ||
2023-05-10 | 2023-03-31 | 0.65 | 0.05 | -0.6 | 92 | ||
2022-05-11 | 2022-03-31 | 0.91 | 0.11 | -0.8 | 87 | ||
2020-11-11 | 2020-09-30 | 0.99 | 0.13 | -0.86 | 86 | ||
2019-11-06 | 2019-09-30 | 0.36 | 1.23 | 0.87 | 241 |
Know Genmab AS's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Genmab AS is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Genmab AS backward and forwards among themselves. Genmab AS's institutional investor refers to the entity that pools money to purchase Genmab AS's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Stifel Financial Corp | 2023-12-31 | 672.9 K | Royal Bank Of Canada | 2023-12-31 | 641 K | Wells Fargo & Co | 2023-12-31 | 557.1 K | Northern Trust Corp | 2023-12-31 | 539 K | Millennium Management Llc | 2023-12-31 | 512.3 K | Hardman Johnston Global Advisors Llc | 2023-12-31 | 482.7 K | American Century Companies Inc | 2023-12-31 | 456.4 K | Point72 Asset Management, L.p. | 2023-09-30 | 278.6 K | Fmr Inc | 2023-12-31 | 267.5 K | Alliancebernstein L.p. | 2023-12-31 | 15.6 M | Blackrock Inc | 2023-12-31 | 4.4 M |
Genmab AS's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 18.09 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Genmab AS's market, we take the total number of its shares issued and multiply it by Genmab AS's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Market Cap |
|
Genmab AS's profitablity analysis
Genmab AS's profitability indicators refer to fundamental financial ratios that showcase Genmab AS's ability to generate income relative to its revenue or operating costs. If, let's say, Genmab AS is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Genmab AS's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Genmab AS's profitability requires more research than a typical breakdown of Genmab AS's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.12 | 0.13 | |
| Return On Capital Employed | 0.16 | 0.17 | |
| Return On Assets | 0.12 | 0.13 | |
| Return On Equity | 0.14 | 0.14 |
Determining Genmab AS's profitability involves analyzing its financial statements and using various financial metrics to determine if Genmab AS is a good buy. For example, gross profit margin measures Genmab AS's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Genmab AS's profitability and make more informed investment decisions.
The data published in Genmab AS's official financial statements usually reflect Genmab AS's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Genmab AS. For example, before you start analyzing numbers published by Genmab accountants, it's critical to develop an understanding of what Genmab AS's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of Genmab AS's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Genmab AS's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Genmab AS's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Genmab AS. Please utilize our Beneish M Score to check the likelihood of Genmab AS's management manipulating its earnings.
Evaluate Genmab AS's management efficiency
Genmab AS has return on total asset (ROA) of 0.1017 % which means that it generated a profit of $0.1017 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1478 %, meaning that it created $0.1478 on every $100 dollars invested by stockholders. Genmab AS's management efficiency ratios could be used to measure how well Genmab AS manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.13. The current year's Return On Capital Employed is expected to grow to 0.17. At present, Genmab AS's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 2.3 B, whereas Non Currrent Assets Other are forecasted to decline to about 41 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 484.00 | 508.20 | |
| Net Current Asset Value | 0.00 | 0.00 | |
| Tangible Asset Value | 0.00 | 0.00 | |
| Tangible Book Value Per Share | 482.45 | 506.58 | |
| Enterprise Value Over EBITDA | (0.01) | (0.01) | |
| Price Book Value Ratio | 0.44 | 0.42 | |
| Enterprise Value Multiple | (0.01) | (0.01) | |
| Price Fair Value | 0.44 | 0.42 | |
| Enterprise Value | -56.3 M | -53.5 M |
The analysis of Genmab AS's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Genmab AS's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Genmab Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 0.78 |
Basic technical analysis of Genmab Stock
As of the 4th of May, Genmab AS retains the Market Risk Adjusted Performance of (0), risk adjusted performance of 0.0063, and Standard Deviation of 2.05. Genmab AS technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to analyze thirteen technical drivers for Genmab AS, which can be compared to its competitors. Please check out Genmab AS treynor ratio, as well as the relationship between the value at risk and skewness to decide if Genmab AS is priced fairly, providing market reflects its last-minute price of 29.72 per share. Given that Genmab AS has information ratio of (0.03), we strongly advise you to confirm Genmab AS's regular market performance to make sure the company can sustain itself at a future point.Understand Genmab AS's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Genmab AS's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0063 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 1.54 | |||
| Coefficient Of Variation | (122,775) | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.19 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 9.14 | |||
| Value At Risk | (3.55) | |||
| Potential Upside | 3.83 | |||
| Skewness | 0.1956 | |||
| Kurtosis | 0.4164 |
| Risk Adjusted Performance | 0.0063 | |||
| Market Risk Adjusted Performance | (0) | |||
| Mean Deviation | 1.54 | |||
| Coefficient Of Variation | (122,775) | |||
| Standard Deviation | 2.05 | |||
| Variance | 4.19 | |||
| Information Ratio | (0.03) | |||
| Jensen Alpha | (0.05) | |||
| Total Risk Alpha | (0.16) | |||
| Treynor Ratio | (0.01) | |||
| Maximum Drawdown | 9.14 | |||
| Value At Risk | (3.55) | |||
| Potential Upside | 3.83 | |||
| Skewness | 0.1956 | |||
| Kurtosis | 0.4164 |
Consider Genmab AS's intraday indicators
Genmab AS intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Genmab AS stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Genmab AS Corporate Filings
6K | 2nd of May 2024 A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges. | ViewVerify |
| 22nd of February 2024 Other Reports | ViewVerify |
Genmab Stock media impact
Far too much social signal, news, headlines, and media speculation about Genmab AS that are available to investors today. That information is available publicly through Genmab media outlets and privately through word of mouth or via Genmab internal channels. However, regardless of the origin, that massive amount of Genmab data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Genmab AS news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Genmab AS relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Genmab AS's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Genmab AS alpha.
Genmab AS Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Genmab AS can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Genmab AS Historical Investor Sentiment
Investor biases related to Genmab AS's public news can be used to forecast risks associated with an investment in Genmab. The trend in average sentiment can be used to explain how an investor holding Genmab can time the market purely based on public headlines and social activities around Genmab AS. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Genmab AS's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Genmab AS and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Genmab AS news discussions. The higher the estimate score, the more favorable the investor's outlook on Genmab AS.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Genmab AS without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Transaction History Now
Transaction HistoryView history of all your transactions and understand their impact on performance |
| All Next | Launch Module |
Genmab AS Corporate Directors
Genmab AS corporate directors refer to members of a Genmab AS board of directors. The board of directors generally takes responsibility for the Genmab AS's affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Genmab AS's board members must vote for the resolution. The Genmab AS board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Takahiro Hamatani | Senior Director | Profile | |
| Daniel Bruno | Director, Employee Representative | Profile | |
| Peter Kristensen | Director, Employee Representative | Profile | |
| Paolo Paoletti | Independent Director | Profile |
How to buy Genmab Stock?
To provide specific investment advice or recommendations on Genmab AS stock, we recommend investors consider the following general factors when evaluating Genmab AS. This will help you to make an informed decision on whether to include Genmab AS in one of your diversified portfolios:- Examine Genmab AS's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Genmab AS's leadership team and their track record. Good management can help Genmab AS navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Genmab AS's business and its evolving consumer preferences.
- Compare Genmab AS's performance and market position to its competitors. Analyze how Genmab AS is positioned in terms of product offerings, innovation, and market share.
- Check if Genmab AS pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Genmab AS's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Genmab AS stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Genmab AS is a good investment.
Already Invested in Genmab AS?
The danger of trading Genmab AS is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Genmab AS is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Genmab AS. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Genmab AS is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Genmab AS offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Genmab AS's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Genmab As Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Genmab As Stock: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genmab AS. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For information on how to trade Genmab Stock refer to our How to Trade Genmab Stock guide.Note that the Genmab AS information on this page should be used as a complementary analysis to other Genmab AS's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Genmab Stock analysis
When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |
Is Genmab AS's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genmab AS. If investors know Genmab will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genmab AS listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.246 | Earnings Share 0.94 | Revenue Per Share 25.2244 | Quarterly Revenue Growth (0.09) | Return On Assets 0.1017 |
The market value of Genmab AS is measured differently than its book value, which is the value of Genmab that is recorded on the company's balance sheet. Investors also form their own opinion of Genmab AS's value that differs from its market value or its book value, called intrinsic value, which is Genmab AS's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genmab AS's market value can be influenced by many factors that don't directly affect Genmab AS's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Genmab AS's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Genmab AS is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genmab AS's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.